| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
37,720,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC™ targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
7,222 |
27,098 |
33,468 |
53,826 |
| Total Sell Value |
$171,618 |
$519,450 |
$663,415 |
$1,227,017 |
| Total People Sold |
7 |
7 |
7 |
9 |
| Total Sell Transactions |
7 |
13 |
25 |
38 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smethurst Dominic |
Chief Medical Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
21,000 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
275,085 |
|
- |
|
| Keen Nicholas |
Chief Scientific Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
23,477 |
|
- |
|
| Jordan Veronica Gh |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Kalowski Lee |
President and CFO |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Kender Richard N |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Bourque Janice |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Guiterrez-Ramos Jose Carlos |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Crockett Nigel |
Chief Business Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Milnes Alistair |
Chief Operating Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-12-22 |
4 |
AS |
$58.01 |
$5,676,859 |
D/D |
(97,860) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-12-22 |
4 |
OE |
$8.48 |
$829,853 |
D/D |
97,860 |
97,860 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-12-21 |
4 |
AS |
$57.11 |
$2,543,508 |
D/D |
(44,537) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-12-21 |
4 |
OE |
$8.44 |
$375,892 |
D/D |
44,537 |
44,537 |
|
- |
|
| Keen Nicholas |
Chief Scientific Officer |
• – – |
2021-12-21 |
4 |
OE |
$14.00 |
$216,678 |
D/D |
15,477 |
15,477 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-12-20 |
4 |
AS |
$57.02 |
$433,523 |
D/D |
(7,603) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-12-20 |
4 |
OE |
$8.41 |
$63,941 |
D/D |
7,603 |
7,603 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-10-18 |
4 |
AS |
$60.00 |
$2,940 |
D/D |
(49) |
225,085 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-10-15 |
4 |
AS |
$60.05 |
$19,216 |
D/D |
(320) |
225,134 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-10-14 |
4 |
AS |
$60.00 |
$277,860 |
D/D |
(4,631) |
225,454 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-10-11 |
4 |
AS |
$53.77 |
$269,388 |
D/D |
(5,000) |
230,085 |
|
- |
|
| Keen Nicholas |
Chief Scientific Officer |
• – – |
2021-10-05 |
4 |
AS |
$45.10 |
$98,228 |
D/D |
(2,178) |
0 |
|
- |
|
| Keen Nicholas |
Chief Scientific Officer |
• – – |
2021-10-01 |
4 |
AS |
$45.00 |
$53,460 |
D/D |
(1,188) |
2,178 |
|
- |
|
| Smethurst Dominic |
Chief Medical Officer |
• – – |
2021-09-23 |
4 |
OE |
$18.55 |
$111,300 |
D/D |
6,000 |
6,000 |
|
- |
|
226 Records found
|
|
Page 4 of 10 |
|
|
